This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de MorphoSys

Salud financiera controles de criterios 2/6

MorphoSys tiene un patrimonio de los accionistas total de €-261.7M y una deuda total de €1.7B, lo que sitúa su ratio deuda-patrimonio en -658%. Sus activos y pasivos totales son €1.8B y €2.1B respectivamente.

Información clave

-658.0%

Ratio deuda-patrimonio

€1.72b

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€630.77m
Patrimonio	-€261.67m
Total pasivo	€2.09b
Activos totales	€1.83b

Actualizaciones recientes sobre salud financiera

Would MorphoSys (ETR:MOR) Be Better Off With Less Debt?

Apr 30

Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?

Aug 24

Recent updates

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Apr 17

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Nov 26

Análisis de la situación financiera

Pasivos a corto plazo: MOR tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: MOR tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: MOR tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: MOR tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MOR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: MOR dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 35.7% cada año

This company listing is no longer active

Salud financiera de hoja de balance de MorphoSys

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Would MorphoSys (ETR:MOR) Be Better Off With Less Debt?

Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?

Recent updates

MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market

MorphoSys AG, Annual General Meeting, Aug 27, 2024

MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market

MorphoSys AG to Report Q2, 2024 Results on Aug 29, 2024

MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance)

MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index

MorphoSys AG Announces Board Changes

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

Novartis Continues to Progress the Workstreams for Implementation of a Delisting of MorphoSys

New major risk - Negative shareholders equity

Consensus EPS estimates fall by 167%

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Would MorphoSys (ETR:MOR) Be Better Off With Less Debt?

Consensus EPS estimates upgraded to €3.87 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Profitability

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Price target increased by 13% to €35.50

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 16%

New minor risk - Shareholder dilution

MorphoSys AG's (ETR:MOR) 93% Share Price Surge Not Quite Adding Up

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Investor sentiment improves as stock rises 43%

Consensus EPS estimates fall by 12%, revenue upgraded

Price target decreased by 8.7% to €31.78

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 17%

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Investor sentiment improves as stock rises 16%

Morphosys AG Provides Earnings Guidance for the Year 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Price target increased by 8.0% to €31.61

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

Is MorphoSys (ETR:MOR) Weighed On By Its Debt Load?

MorphoSys AG Provides Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to €25.94

Consensus EPS estimates upgraded to €6.45 loss

Does MorphoSys (ETR:MOR) Have A Healthy Balance Sheet?

Consensus estimates of losses per share improve by 12%

Price target increased by 7.3% to €19.64

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

MorphoSys AG (ETR:MOR) Held Back By Insufficient Growth Even After Shares Climb 36%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 27% to €18.25

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

Price target decreased to €24.05

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Price target decreased to €26.50

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

MorphoSys AG (ETR:MOR) Analysts Are More Bearish Than They Used To Be

Consensus forecasts updated

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance